GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
You may also be interested in...
GSK’s Malaria Vaccine To Be Made By Bharat Biotech For WHO
GSK is transferring technology for the manufacture of its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower costs for such programs.
Vaccine Stability Improvements Sought By GSK, Sanofi And Gates Foundation
GSK’s malaria vaccine candidate is lead candidate in effort to solve the cold-chain storage problem.
Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines
Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.